The filing relates to the sale or other disposition from time to time of (i) up to 21.66M shares of common stock issuable upon the exercise of warrants, (ii) up to 15.3M shares of common stock issuable upon the exercise of pre-funded warrants, and (iii) up to 2.86M shares of common stock issuable upon the exercise of warrants issued to placement agents all held by the selling stockholders, including their transferees, pledgees, donees or successors. The company is not selling any warrants to purchase common stock, pre-funded warrants to purchase common stock, or placement agent warrants to purchase common stock under this prospectus and will not receive any of the proceeds from the sale of the shares underlying such securities by the selling stockholders.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTOR:
- Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
- Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
- Citius Oncology Raises $18M Through Direct Offering
- Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
- Citius Oncology expands Lymphir distribution to Turkey and Middle East
